Shell Asset Management Co. Buys New Shares in Doximity, Inc. (NASDAQ:DOCS)

Shell Asset Management Co. bought a new stake in Doximity, Inc. (NASDAQ:DOCS – Get Rating) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,937 shares of the company’s stock, valued at approximately $65,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. James Investment Research Inc. acquired a new stake in Doximity in the fourth quarter valued at $27,000. Signaturefd LLC raised its stake in Doximity by 98.1% in the third quarter. Signaturefd LLC now owns 1,050 shares of the company’s stock valued at $32,000 after buying an additional 520 shares in the last quarter. Sentry Investment Management LLC acquired a new stake in Doximity in the third quarter valued at $38,000. American International Group Inc. acquired a new stake in Doximity in the second quarter valued at $43,000. Finally, CWM LLC raised its stake in Doximity by 540.4% in the third quarter. CWM LLC now owns 1,460 shares of the company’s stock valued at $44,000 after buying an additional 1,232 shares in the last quarter. 52.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DOCS has been the topic of a number of research analyst reports. Canaccord Genuity Group cut their target price on Doximity from $42.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, February 10th. Wells Fargo & Company cut Doximity from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $39.00 to $37.00 in a research report on Monday, May 1st. JPMorgan Chase & Co. cut their target price on Doximity from $60.00 to $30.00 and set an “underweight” rating on the stock in a research report on Friday, February 17th. Needham & Company LLC reiterated a “buy” rating and set a $45.00 target price on shares of Doximity in a research report on Friday, February 10th. Finally, Piper Sandler boosted their price target on Doximity from $35.00 to $38.00 in a research report on Friday, February 10th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $40.38.

Doximity Trading Down 0.4 %

Shares of DOCS opened at $33.04 on Friday. Doximity, Inc. has a twelve month low of $22.91 and a twelve month high of $47.46. The stock’s 50 day moving average is $33.26 and its two-hundred day moving average is $32.92. The firm has a market capitalization of $6.40 billion, a PE ratio of 60.07, a P/E/G ratio of 15.27 and a beta of 0.87.

Doximity (NASDAQ:DOCS – Get Rating) last announced its quarterly earnings results on Thursday, February 9th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.13 by $0.04. The business had revenue of $115.26 million for the quarter, compared to analyst estimates of $111.20 million. Doximity had a return on equity of 13.64% and a net margin of 29.59%. On average, sell-side analysts predict that Doximity, Inc. will post 0.51 EPS for the current year.

Insider Transactions at Doximity

In other news, Director Timothy S. Cabral sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, April 11th. The stock was sold at an average price of $35.00, for a total transaction of $262,500.00. Following the sale, the director now owns 4,714 shares of the company’s stock, valued at approximately $164,990. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 45.21% of the company’s stock.

About Doximity

(Get Rating)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.